In a recently-filed 13G, James E. Flynn‘s Deerfield Management disclosed its position in XenoPort, Inc. (NASDAQ:XNPT). According to the filing with the Securities and Exchange Commission, Deerfield owns a 10.55% position in Xenoport, which contains 6.67 million shares. According to Deerfield’s last 13F filing, the fund initiated a stake in Xenoport during the third quarter of 2015, reporting 3.45 million shares as of the end of September.
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1) *
(Name of Issuer)
(Title of Class of Securities)
January 20, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
(Page 1 of 9 Pages)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Biotech Stock Alert - 20% Guaranteed Return in One Year
Hedge Funds and Insiders Are Piling Into
One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.
Get your FREE REPORT and the details of our 20% return guarantee today.